Scarica l'app Stockscreener
6.25
11.81%
0.66
Dopo l'orario di chiusura:
6.20
-0.05
-0.80%
Sionna Therapeutics Inc Borsa (SION) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect - ACCESS Newswire
Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move - vinanet.vn
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - Yahoo Finance
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
2026-08-20 | Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SION | Press Release - Stockhouse
Sionna (SION) Quarterly Figures: The Bottom-Line Figure Beats Its Comparison in the Current Update; Trading Response: The Share Price Adds 5.22% for the Current SessionTangible Book Value - vinanet.vn
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sionna shares plunge 92% after Phase 2a trial o... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sionna Therapeutics (SION) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - FinancialContent
Sionna Therapeutics, Inc. Common Stock (NASDAQ: SION) Stock Price, News & Analysis - Kalkine
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information - Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION) - GlobeNewswire
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? - Stocktwits
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - The Daily Tribune News
symbol__ Stock Quote Price and Forecast - CNN
Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION) - Business Wire
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - PR Newswire
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? - Yahoo Finance
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed? - Yahoo Finance
SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - PR Newswire
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) - Morningstar
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sionna's SION-719 Failure Changes Everything (Rating Downgrade) - Seeking Alpha
Sionna Therapeutics (NASDAQ:SION) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading - MarketBeat
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall - Yahoo Finance
SIONNA THERAPEUTICS, INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $5 FROM $53 - webull.com
SION Q2 2026 Earnings: Narrower $0.66 Loss Drives 16.4% Jump in SharesFinancial Summary - vinanet.vn
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses - finance.yahoo.com
SION Stock Slides, Then Snaps Back As Traders Eye Volatility - StocksToTrade
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates - GlobeNewswire
Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com
BTIG Downgrades Sionna Therapeutics to Neutral From Buy - marketscreener.com
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure - Yahoo Finance
Accendra Health, Celestica, Sionna Therapeutics - TradingView
SIONNA THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Sionna Therapeutics, Inc.Common Stock (SION) Stock Price, News, Quote & History - FinancialContent
SIONNA THERAPEUTICS, INC. : JONESTRADING CUTS TO HOLD RATING - Bitget
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path - TradingView
Sionna shares plummet after cystic fibrosis clinical trial failure - mugglehead.com
Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low -- Barrons.com - Moomoo
Health Care Up on Rotation to Less Inflation Sensitive SectorsHealth Care Roundup - Moomoo
Sionna Therapeutics: Hold Rating Maintained as Disappointing CF Data Drive Price Target Cut from $60 to $6 - TipRanks
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
Sionna Therapeutics (NASDAQ:SION) Downgraded to "Neutral" Rating by BTIG Research - MarketBeat
BTIG downgrades Sionna Therapeutics stock rating after trial miss By Investing.com - Investing.com Canada
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low - Barron's
Guggenheim Reiterates Neutral Rating for Sionna Therapeutics (NASDAQ:SION) - marketbeat.com
Guggenheim downgrades Sionna Therapeutics stock rating after trial failure By Investing.com - Investing.com Canada
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks - Benzinga
Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash - TechStock²
Sionna Therapeutics stock plunges nearly 100% after cystic fibrosis drug fails key trial - The Business Journals
Raymond James downgrades Sionna Therapeutics stock rating on trial failure - Investing.com
Raymond James downgrades Sionna Therapeutics stock rating on trial failure By Investing.com - Investing.com Canada
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex - biopharmadive.com
Vertex Shares Hit Record as Sionna's Cystic Fibrosis Failure Removes Key Overhang - finance.biggo.com
Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge - Benzinga
Sionna Therapeutics' (SION) "Neutral" Rating Reiterated at Wedbush - MarketBeat
0.07%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):